Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$1.06
-2.8%
$1.64
$1.04
▼
$2.58
$290.31M2.322.65 million shs2.56 million shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.96
-3.0%
$2.17
$1.43
▼
$3.23
$191.00M2.85212,478 shs145,904 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.10
+0.7%
$7.00
$3.53
▼
$11.29
$196.95M1.34447,595 shs370,343 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-2.75%-14.17%-33.33%-56.91%-17.83%
Compugen Ltd. stock logo
CGEN
Compugen
-2.97%-6.22%-0.51%-26.04%+20.99%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+0.71%-22.40%+14.70%-18.58%+36.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$1.06
-2.8%
$1.64
$1.04
▼
$2.58
$290.31M2.322.65 million shs2.56 million shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.96
-3.0%
$2.17
$1.43
▼
$3.23
$191.00M2.85212,478 shs145,904 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.10
+0.7%
$7.00
$3.53
▼
$11.29
$196.95M1.34447,595 shs370,343 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-2.75%-14.17%-33.33%-56.91%-17.83%
Compugen Ltd. stock logo
CGEN
Compugen
-2.97%-6.22%-0.51%-26.04%+20.99%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+0.71%-22.40%+14.70%-18.58%+36.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.88
Moderate Buy$10.00843.40% Upside
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$5.00155.10% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
2.60
Moderate Buy$32.25354.23% Upside

Current Analyst Ratings Breakdown

Latest AUTL, CGEN, and DTIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Compugen Ltd. stock logo
CGEN
Compugen
Reiterated RatingBuy
11/11/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Reiterated RatingBuy
11/11/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Reiterated RatingBuy
11/3/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/3/2026
Compugen Ltd. stock logo
CGEN
Compugen
Reiterated RatingHold (C-)
11/3/2026
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
Reiterated RatingSell (D-)
11/2/2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Initiated CoverageBuy
10/12/2026
Compugen Ltd. stock logo
CGEN
Compugen
Reiterated RatingBuy$4.00
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$75.39M3.74N/AN/A$0.10 per share10.60
Compugen Ltd. stock logo
CGEN
Compugen
$75.93M2.44$0.36 per share5.41$0.88 per share2.23
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$45.04M4.40N/AN/A$1.85 per share3.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$287.53M-$0.97N/AN/AN/A-186.37%-263.25%-48.04%N/A
Compugen Ltd. stock logo
CGEN
Compugen
$35.34M$0.395.03N/AN/A47.90%39.30%25.51%N/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$45.72M-$1.24N/AN/AN/A-96.73%-56.69%-27.63%N/A

Latest AUTL, CGEN, and DTIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.21-$0.21N/A-$0.21$39.54 million$41.24 million
11/9/2026Q3 2026
Compugen Ltd. stock logo
CGEN
Compugen
-$0.0802-$0.06+$0.0202-$0.06$1.29 million$3.82 million
11/3/2026Q3 2026
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.85-$0.28+$0.57-$0.28$1.38 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
5.25
3.72
3.36
Compugen Ltd. stock logo
CGEN
Compugen
N/A
4.90
4.90
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.43
10.47
10.47

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
25.70%
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
752266.34 million197.89 millionOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7594.55 million85.57 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
6927.94 million27.18 millionOptionable

Recent News About These Companies

Precision BioSciences raises $125M in offering
HC Wainwright Has Bullish Estimate for DTIL FY2026 Earnings
Precision BioSciences Inc (DTIL)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$1.06 -0.03 (-2.75%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.10 +0.03 (+3.30%)
As of 11/18/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Compugen stock logo

Compugen NASDAQ:CGEN

$1.96 -0.06 (-2.97%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.98 +0.02 (+1.02%)
As of 11/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$7.10 +0.05 (+0.71%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$7.10 0.00 (-0.07%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.